Skip to content

Tarsus Pharmaceuticals, Inc. TARS Tenant improvement allowance

Tenant improvement allowance at other companies

Evercore logo
EvercoreEVR
$16.56M-4.3%
PJT Partners logo
PJT PartnersPJT
$17.22M-47.9%
Schering-Plough logo
Schering-PloughSGP
$2.2M
Vestis logo
VestisVSTS
$25K-97.8%
Enphase Energy logo
Enphase EnergyENPH
$0-100%
LiveRamp Holdings, Inc. logo
LiveRamp Holdings, Inc.RAMP
$0+100%

Other financials

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%
P/S5.3×-3.3×

Profitability

See full
Gross margin42.7%
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept tars:LesseeTenantImprovementAllowance.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s tenant improvement allowance.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s tenant improvement allowance?
Tarsus Pharmaceuticals, Inc. (TARS) reported tenant improvement allowance of $5.8M in Q4 2024.
What does tenant improvement allowance mean?
This represents the funding provided by a landlord to a tenant to cover the costs of customizing or renovating leased space. It is a vital component of capital expenditure management, as it reduces the net cash outlay required for facility setup.